Brief: Novartis AG - Receives Positive CHMP Opinion For Itvisma For Spinal Muscular Atrophy (SMA)
24/04/2026 11:34
April 24 (Reuters) - Novartis AG NOVN.S: NOVARTIS AG - RECEIVES POSITIVE CHMP OPINION FOR ITVISMA FOR SPINAL MUSCULAR ATROPHY (SMA) Source text: ID:nGNE2khg8G Further company coverage: NOVN.S (Gdansk Newsroom) (((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'